Greylin Investment Mangement Inc. decreased its holdings in GlaxoSmithKline plc (NYSE:GSK) by 38.9% in the fourth quarter, Holdings Channel reports. The fund owned 68,025 shares of the pharmaceutical company’s stock after selling 43,385 shares during the period. GlaxoSmithKline accounts for approximately 0.5% of Greylin Investment Mangement Inc.’s investment portfolio, making the stock its 29th largest holding. Greylin Investment Mangement Inc.’s holdings in GlaxoSmithKline were worth $2,413,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in GSK. Principal Financial Group Inc. acquired a new stake in GlaxoSmithKline in the 2nd quarter valued at about $602,000. King Luther Capital Management Corp raised its holdings in GlaxoSmithKline by 1.0% in the 2nd quarter. King Luther Capital Management Corp now owns 5,432 shares of the pharmaceutical company’s stock valued at $234,000 after acquiring an additional 55 shares during the last quarter. Bahl & Gaynor Inc. raised its holdings in GlaxoSmithKline by 0.9% in the 2nd quarter. Bahl & Gaynor Inc. now owns 17,481 shares of the pharmaceutical company’s stock valued at $673,000 after acquiring an additional 150 shares during the last quarter. Stevens Capital Management LP raised its holdings in GlaxoSmithKline by 17.1% in the 2nd quarter. Stevens Capital Management LP now owns 40,674 shares of the pharmaceutical company’s stock valued at $1,754,000 after acquiring an additional 5,933 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its holdings in GlaxoSmithKline by 0.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 1,133,608 shares of the pharmaceutical company’s stock valued at $48,881,000 after acquiring an additional 3,698 shares during the last quarter. Institutional investors own 9.80% of the company’s stock.

Several research firms have recently weighed in on GSK. UBS Group raised shares of GlaxoSmithKline from a “neutral” rating to a “buy” rating and increased their price target for the company from $35.04 to $35.85 in a research note on Monday, November 27th. Cowen set a $38.00 price target on shares of GlaxoSmithKline and gave the company a “hold” rating in a research note on Monday, December 11th. ValuEngine cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Barclays raised shares of GlaxoSmithKline from an “equal weight” rating to an “overweight” rating in a research note on Tuesday. Finally, Zacks Investment Research cut shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a research note on Tuesday, October 24th. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have issued a buy rating to the company. GlaxoSmithKline has a consensus rating of “Hold” and an average price target of $38.57.

In other GlaxoSmithKline news, major shareholder Plc Glaxosmithkline bought 428,571 shares of GlaxoSmithKline stock in a transaction on Monday, November 6th. The shares were bought at an average cost of $14.00 per share, for a total transaction of $5,999,994.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 10.00% of the stock is owned by corporate insiders.

GlaxoSmithKline plc (NYSE:GSK) traded up $0.66 during trading hours on Tuesday, hitting $37.50. 4,999,600 shares of the company were exchanged, compared to its average volume of 6,065,456. The company has a debt-to-equity ratio of 2.96, a current ratio of 0.64 and a quick ratio of 0.44. The stock has a market cap of $93,290.00, a PE ratio of 28.63, a P/E/G ratio of 2.15 and a beta of 0.97. GlaxoSmithKline plc has a 1 year low of $34.52 and a 1 year high of $44.53.

GlaxoSmithKline (NYSE:GSK) last posted its quarterly earnings data on Wednesday, October 25th. The pharmaceutical company reported $0.85 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.84 by $0.01. GlaxoSmithKline had a net margin of 7.79% and a return on equity of 115.30%. equities analysts predict that GlaxoSmithKline plc will post 2.9 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, January 11th. Shareholders of record on Friday, November 10th were issued a dividend of $0.5037 per share. The ex-dividend date was Thursday, November 9th. This is a positive change from GlaxoSmithKline’s previous quarterly dividend of $0.49. This represents a $2.01 dividend on an annualized basis and a yield of 5.37%. GlaxoSmithKline’s dividend payout ratio is 155.73%.

COPYRIGHT VIOLATION NOTICE: “Greylin Investment Mangement Inc. Sells 43,385 Shares of GlaxoSmithKline plc (GSK)” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2018/01/16/greylin-investment-mangement-inc-sells-43385-shares-of-glaxosmithkline-plc-gsk.html.

GlaxoSmithKline Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Stock Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related stocks with our FREE daily email newsletter.